Daptomycin for Vancomycin-Resistant Enterococcal Infection: A Review of the Clinical Effectiveness, Cost-Effectiveness and Guidelines


( Last Updated : January 14, 2016)
Project Line:
Health Technology Review
Project Sub Line:
Summary with Critical Appraisal
Project Number:
RC0738-000

Details


Question


  1. What is the comparative clinical effectiveness and safety of daptomycin versus alternative antibiotic therapies for VRE bacteremia or infection?

  2. What is the cost-effectiveness of daptomycin versus alternative antibiotic therapies for VRE bacteremia or infection?

  3. What are the evidence-based guidelines regarding the optimal dose of daptomycin for VRE bacteremia or infection?

  4. What are the evidence-based guidelines regarding the use of daptomycin for VRE bacteremia or infection?


Key Message

Evidence from one systematic review (SR) and three non-randomized studies is inconsistent regarding the comparative effectiveness and safety of daptomycin in patients with VRE infection. In particular, some studies suggest that daptomycin is similar to linezolid or -lactams, while others favour one therapy over another. However, several important limitations exist among these studies, which threaten the validity of the evidence and limit its utility for decision-making. No evidence was found regarding the cost-effectiveness of daptomycin versus alternative antibiotic therapies in patients with VRE infection. Further, no evidence-based guidelines on the optimal use of daptomycin in patients with VRE infection were found.